Nuclear location of synthetic oligonucleotides microinjected somatic cells: its implication in an antisense strategy. 1991

N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
Laboratoire de Biochimie des Proteines, UA CNRS 1191, Université de Montpellier II, Montpellier, France.

Synthetic oligonucleotides are widely used to modulate gene expression. However their development as genetic tools and as molecule of therapeutic interest is restricted by the poor knowledge of their mechanism of action and of their uptake by cells. We recently found that microinjected oligonucleotides accumulates in the nucleus of the cells. These observations are described and their implications are discussed.

UI MeSH Term Description Entries
D008845 Microinjections The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes. Microinjection
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012342 RNA, Small Nuclear Short chains of RNA (100-300 nucleotides long) that are abundant in the nucleus and usually complexed with proteins in snRNPs (RIBONUCLEOPROTEINS, SMALL NUCLEAR). Many function in the processing of messenger RNA precursors. Others, the snoRNAs (RNA, SMALL NUCLEOLAR), are involved with the processing of ribosomal RNA precursors. Low Molecular Weight Nuclear RNA,Small Nuclear RNA,snRNA,Chromatin-Associated RNA,Small Molecular Weight RNA,Chromatin Associated RNA,RNA, Chromatin-Associated
D014721 Vesicular stomatitis Indiana virus The type species of VESICULOVIRUS causing a disease symptomatically similar to FOOT-AND-MOUTH DISEASE in cattle, horses, and pigs. It may be transmitted to other species including humans, where it causes influenza-like symptoms. Vesicular stomatitis-Indiana virus
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense
D016895 Culture Media, Serum-Free CULTURE MEDIA free of serum proteins but including the minimal essential substances required for cell growth. This type of medium avoids the presence of extraneous substances that may affect cell proliferation or unwanted activation of cells. Protein-Free Media,Serum-Free Media,Low-Serum Media,Culture Media, Serum Free,Low Serum Media,Media, Low-Serum,Media, Protein-Free,Media, Serum-Free,Media, Serum-Free Culture,Protein Free Media,Serum Free Media,Serum-Free Culture Media

Related Publications

N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
December 1990, Experimental cell research,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
January 1999, Toxicologic pathology,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
June 2001, Current opinion in molecular therapeutics,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
January 2014, Methods in molecular biology (Clifton, N.J.),
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
January 2023, Frontiers in pharmacology,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
January 1984, Ciba Foundation symposium,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
February 1995, The International journal of developmental biology,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
October 2001, Cancer biotherapy & radiopharmaceuticals,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
May 1998, Molecular biology of the cell,
N Mechti, and J P Leonetti, and J P Clarenc, and G Degols, and B Lebleu
August 1996, Nuklearmedizin. Nuclear medicine,
Copied contents to your clipboard!